NDATOPICALGEL
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
CABTREO (clindamycin phosphate/benzoyl peroxide/adapalene) by Bausch + Lomb. Approved for retinoid [epc]. First approved in 2023.
Drug data last refreshed 8h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CABTREO is a fixed-dose topical gel combining clindamycin phosphate (antibiotic), benzoyl peroxide (keratolytic/antimicrobial), and adapalene (retinoid) approved October 2023 for acne treatment. The three-component formulation targets acne through anti-inflammatory, antimicrobial, and cell turnover mechanisms in a single application. It represents a modernized triple-combination approach to topical acne therapy.
Growth14.5 years to LOE
Early-stage growth product with 14.5 years of exclusivity provides stable career runway; small competitor set and recent approval suggest ramping commercial infrastructure.
Mechanism of Action
Pharmacologic Class:
Retinoid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo
Started Apr 2026
100 enrolled
Acne Vulgaris
Career Relevance
CABTREO is a newly launched topical product entering growth phase with 14+ years of patent protection, creating opportunities across commercial, medical affairs, and market access roles. Bausch + Lomb's established dermatology portfolio provides a stable platform for career development in a specialty-focused organization.
Brand Manager
Worked on CABTREO at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.